Peptidomimetic-based approach toward inhibitors of microbial trimethylamine lyases

Research output: Contribution to journalArticle


The development of gut microbiota-targeted small molecules represents a promising platform for the identification of new therapeutics based on the implication of human gut bacteria with different diseases. Bacterial trimethylamine (TMA)-lyase (CutC) is expressed in gut bacteria and catalyzes the conversion of choline to TMA. The association of elevated TMA production with various disorders has directed research efforts toward identification of CutC inhibitors. Herein, we introduce peptidomimetics as a promising toolbox for the discovery of CutC inhibitors. Our approach starts with screening a library of peptidomimetics for intestinal metabolic stability followed by in vitro CutC inhibition. Compound 5 was identified from this screening platform with IC50 value of 5.9 ± 0.6 μM for CutC inhibition. Unlike previously reported CutC inhibitors, compound 5 possessed universal CutC inhibitory activity in different bacterial strains. Molecular dynamics simulations suggested a plausible binding site and inhibition mechanism for compound 5. Therefore, compound 5 is a promising lead for further structural optimization in the search for CutC-targeted small molecules.

Original languageEnglish
Pages (from-to)(In-Press)
JournalChemical Biology and Drug Design
Early online date19 Aug 2020
Publication statusE-pub ahead of print - 19 Aug 2020


  • choline metabolism
  • gut microbiota
  • peptidomimetics
  • trimethylamine lyase

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Peptidomimetic-based approach toward inhibitors of microbial trimethylamine lyases'. Together they form a unique fingerprint.

  • Cite this